Novel tests based on large-scale protein measurements will first offer personal and precise information about an individual’s cardiometabolic health status and trajectory
SomaLogic today launched its first seven SomaSignal™ tests, which are delivered simultaneously to provide actionable health information across a diverse set of human diseases and conditions. Each SomaSignal™ test is built on SomaLogic’s proprietary SomaScan® Platform, which measures thousands of human proteins in a single blood sample. Applying sophisticated computer algorithms translates those protein measurements into meaningful, personalized health information for the individual being tested. The company expects that eventually there will be hundreds of different SomaSignal™ tests on the SomaScan® Platform.
“Proteins are the most accurate and relevant measure of what is happening in your body in real time,” said Stephen Williams, SomaLogic’s Chief Medical Officer. “By measuring thousands (as opposed to one or even a handful) of proteins in these SomaSignal™ tests, we gain a more comprehensive view of an individual’s current health states, the impact of modifiable behaviors and their near-term risk for future disease development. This information can then be used to tailor effective strategies for every person to proactively manage their health.”
The first seven SomaSignal™ tests that can be measured from a single blood sample and that are being launched today include:
- Primary cardiovascular risk – risk of a heart attack, stroke, heart failure or cardiovascular death within the next 4 years in people without known heart disease
- Secondary cardiovascular risk – risk of a heart attack, stroke, heart failure or cardiovascular death within the next 4 years in people with previously known heart disease
- Alcohol impact – whether or not the body shows effects of more than 7 drinks per week
- Liver fat – presence of excess fat in the liver
- Body fat percentage – percentage of overall body fat
- Lean body mass – percentage of lean tissue mass in the body
- Cardiorespiratory fitness – actual aerobic fitness level (similar to treadmill VO2 max test)
These new SomaSignal™ tests are initially available only through a prescribing physician at a limited number of Colorado-based practices, but there is a plan to scale across the United States.
“The launch of these first tests is just the beginning of bringing a new, transformational technology to bear on improving health across many diseases and markets,” said SomaLogic’s Chief Executive Officer, Roy Smythe, M.D. “Over time, we will methodically increase the number and geographic coverage of participating physician practices, as well as the number of different SomaSignal™ tests available at those practices.”
With repeated SomaSignal™ testing over time, individuals will be able to continuously monitor their health, respond proactively to adverse changes in their health and determine the effectiveness of medication, diet or lifestyle modifications across a wide variety of conditions. These “real-time” and more comprehensive attributes distinguish SomaSignal™ protein (proteomics) tests from typical gene (genomics) tests, which only provide partial information about the potential lifetime risk of developing certain types of disease.
For further information about SomaSignal™ tests and the SomaScan® Platform, please visit www.somalogic.com. The SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have not been cleared or approved by the US Food and Drug Administration.